NIAID appears on track to have Zika vaccine in widespread testing in late 2017, but development depends in part on the epidemic rate; additional funding is necessary to respond to the outbreak, NIAID director and CDC official testify at Senate and House hearings.
National Institute of Allergy and Infectious Diseases Director Anthony Fauci suggested at a Senate hearing that a Zika virus vaccine could be available for widespread testing in 2017 – if the epidemic continues at its current rate.
But Fauci's exchange with Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-TN, on Feb. 24 underscored the challenge of vaccine development, as a diminishing outbreak can mean longer...
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.
Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered.
For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.
Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
